Apimeds Pharmaceuticals US (APUS) is the biggest gainer in this regular-hours session, with shares up 252.21% to $7.96 as of the latest print. The stock opened at $6.99 and pulled volume of more than 34 million shares, compared to an average daily volume of roughly 249,000 based on short-interest data.

What We Know About the Move

The session's surge in APUS is not clearly tied to a single, datable news item or SEC filing released today. Several recent developments appear to be contributing to heightened speculative interest.

IBN Coverage Initiation On September 18, 2026, IBN initiated coverage of Apimeds Pharmaceuticals US. That report may be circulating among retail and small-cap investors this week.

Merger and PIPE Financing Apimeds has been working through a complex corporate restructuring. In May 2026, the company announced it settled a dispute with Inscobee, allowing a previously stalled merger to proceed. A $100 million PIPE financing was set to close as part of that arrangement. Separately, in December 2025, Apimeds and MindWave Innovations announced a merger integrating biotech growth with an AI-driven digital treasury strategy backed by 1,000 Bitcoin.

FDA Engagement on Apitox The company and partner Lōkahi Therapeutics have been advancing Apitox, a non-opioid pain treatment targeting osteoarthritis and multiple sclerosis. An FDA Type C meeting was scheduled for early 2026, and the company previously welcomed FDA draft guidance as a potential catalyst for the Apitox program.

Company Background

Apimeds Pharmaceuticals US operates as a clinical-stage biopharmaceutical firm. Its flagship product, Apitox, is an active pharmaceutical ingredient designed to address inflammation and pain. The company is headquartered in Hopewell, New Jersey, and functions as a subsidiary of Api Meds, Inc. With only two employees and a market cap near $112 million, APUS is a micro-cap biotech with high volatility risk.

Key Context for Today's Move

  • Float: Approximately 226.5 million shares outstanding
  • Days to cover: 1.00 based on short interest of roughly 19.9 million shares
  • Recent filings: Multiple 8-Ks have been filed in recent weeks, including one on September 22, 2026, though the substance of that filing is not detailed in the available sources

APUS has thin average daily volume, making it susceptible to outsized percentage moves when a pickup in buying activity occurs. The combination of ongoing merger developments, FDA engagement on its pain-management drug, and broader biotech interest may be drawing speculative capital into the name today.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.